Yan Weng Selected Research

PF-05231023

1/2018	Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing.
12/2017	Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates.
3/2016	A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects.
1/2015	Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yan Weng Research Topics

Disease

7	Body Weight (Weight, Body) 01/2018 - 01/2005
6	Type 2 Diabetes Mellitus (MODY) 07/2022 - 04/2014
6	Inflammation (Inflammations) 02/2019 - 01/2012
5	Reperfusion Injury 07/2022 - 01/2013
5	Infarction (Infarctions) 02/2019 - 11/2013
4	Obesity 07/2022 - 03/2016
4	Insulin Resistance 01/2021 - 01/2017
4	Hyperglycemia 01/2017 - 08/2006
3	Brain Ischemia (Cerebral Ischemia) 07/2022 - 01/2014
3	Fatty Liver 01/2022 - 09/2005
3	Wounds and Injuries (Trauma) 01/2021 - 12/2015
3	Chronic Renal Insufficiency 01/2020 - 01/2015
3	Diabetic Cardiomyopathies 01/2017 - 01/2015
2	Alcoholic Fatty Liver 07/2022 - 01/2021
2	Non-alcoholic Fatty Liver Disease 07/2022 - 11/2020
2	Ischemic Stroke 07/2022 - 02/2019
2	Metabolic Diseases (Metabolic Disease) 01/2021 - 01/2018
2	Neoplasms (Cancer) 07/2019 - 08/2007
2	Weight Loss (Weight Reduction) 12/2017 - 03/2014
2	Ischemia 01/2017 - 01/2014
2	Diabetes Mellitus 04/2015 - 03/2014
2	Myocardial Ischemia (Ischemic Heart Diseases) 11/2013 - 01/2013
2	Lipidoses 09/2005 - 01/2005
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 07/2022
1	Polyps 06/2022
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 06/2022
1	Developmental Dysplasia of the Hip 05/2022
1	Hip Dislocation 05/2022
1	Alzheimer Disease (Alzheimer's Disease) 02/2022
1	Hypertriglyceridemia 01/2021
1	Hyperlipidemias (Hyperlipidemia) 01/2021
1	Hyperinsulinism (Hyperinsulinemia) 01/2021
1	Postherpetic Neuralgia 07/2020
1	Kidney Diseases (Kidney Disease) 01/2020
1	Colorectal Neoplasms (Colorectal Cancer) 07/2019
1	Neuroinflammatory Diseases 02/2019
1	Brain Edema (Cerebral Edema) 02/2019
1	Cardiovascular Diseases (Cardiovascular Disease) 07/2018
1	Chronic Kidney Disease-Mineral and Bone Disorder (Renal Rickets) 05/2018
1	Breast Neoplasms (Breast Cancer) 11/2017
1	Tuberculosis (Tuberculoses) 06/2017
1	Dyslipidemias (Dyslipidemia) 01/2017
1	Macular Degeneration (Age-Related Maculopathy) 04/2016

Drug/Important Bio-Agent (IBA)

5	EnzymesIBA 07/2022 - 11/2013
5	Pharmaceutical PreparationsIBA 02/2022 - 06/2010
5	AntioxidantsIBA 01/2021 - 01/2014
5	LipidsIBA 01/2021 - 03/2016
4	FructoseIBA 07/2022 - 01/2017
4	Proteins (Proteins, Gene)FDA Link 01/2021 - 08/2015
4	Streptozocin (Streptozotocin)FDA Link 01/2021 - 08/2006
4	CytokinesIBA 02/2019 - 11/2013
4	PF-05231023IBA 01/2018 - 01/2015
3	Glucose (Dextrose)FDA LinkGeneric 07/2022 - 04/2014
3	Blood Glucose (Blood Sugar)IBA 01/2020 - 01/2008
3	chikusetsu saponin IVaIBA 01/2020 - 12/2015
3	fibroblast growth factor 21IBA 01/2018 - 03/2016
3	AdiponectinIBA 12/2017 - 01/2016
3	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2017 - 01/2015
2	ketohexokinaseIBA 07/2022 - 01/2022
2	Neuroprotective AgentsIBA 07/2022 - 02/2019
2	Peroxidase (Myeloperoxidase)IBA 07/2018 - 11/2013
2	hsian-tsaoIBA 06/2008 - 01/2008
2	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 08/2007 - 09/2005
2	CholesterolIBA 09/2005 - 01/2005
1	Oxygen (Dioxygen)IBA 07/2022
1	Protein Kinase C-epsilonIBA 07/2022
1	Heme Oxygenase-1IBA 07/2022
1	boswellic acidIBA 07/2022
1	SodiumIBA 02/2022
1	Peptides (Polypeptides)IBA 01/2022
1	AnionsIBA 01/2022
1	PalmitatesIBA 01/2021
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2020
1	Fibrinogen (Factor I)FDA Link 07/2019
1	ApelinIBA 02/2019
1	Small Interfering RNA (siRNA)IBA 02/2019
1	Calcium-Calmodulin-Dependent Protein Kinase KinaseIBA 02/2019
1	Thymic Stromal LymphopoietinIBA 01/2019
1	ThiouracilIBA 07/2018
1	acetamideIBA 07/2018
1	MineralsIBA 05/2018
1	Phosphates (Orthophosphate)IBA 05/2018
1	AntigensIBA 02/2018
1	Atorvastatin (Lipitor)FDA Link 12/2017
1	Triglycerides (Triacylglycerol)IBA 12/2017
1	HDL CholesterolIBA 12/2017
1	Proline (L-Proline)FDA Link 11/2017
1	Biomarkers (Surrogate Marker)IBA 11/2017
1	antineoplaston A10 (A 10)IBA 06/2017
1	butinIBA 01/2017
1	Vitamin D FDA LinkGeneric 04/2016
1	Insulin-Like PeptidesIBA 03/2016
1	Lipoproteins (Lipoprotein)IBA 03/2016

Therapy/Procedure

4	Cardiopulmonary Resuscitation (CPR) 07/2010 - 01/2005
3	Therapeutics 01/2020 - 01/2013
3	Chinese Traditional Medicine (Traditional Chinese Medicine) 04/2015 - 06/2013
1	Endoscopes 06/2022
1	Hip Replacement Arthroplasty (Total Hip Replacement) 05/2022
1	Osteotomy 05/2022
1	Extracorporeal Shockwave Therapy 07/2020